Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism

<jats:p> </jats:p>

[1]  D. Boulware,et al.  Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization , 2022, JAMA network open.

[2]  Alexandra Papadopoulou,et al.  Anti-SARS-CoV-2 Action of 5α-Reductase Inhibitors May be Mediated by Dehydroepiandrosterone. , 2022, The Journal of urology.

[3]  Te Jiang,et al.  Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway , 2022, Inflammation.

[4]  K. Hashimoto,et al.  Mechanisms of action of fluvoxamine for COVID-19: a historical review , 2022, Molecular Psychiatry.

[5]  N. Aghaeepour,et al.  Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants , 2021, JAMA network open.

[6]  T. Aw,et al.  Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase , 2021, Pharmacopsychiatry.

[7]  Jun Zhu,et al.  Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway , 2021, Acta Pharmacologica Sinica.

[8]  J. Bernatonienė,et al.  An Overview of NO Signaling Pathways in Aging , 2021, Molecules.

[9]  S. Orfanos,et al.  Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) , 2021, Pharmaceuticals.

[10]  J. Tanner,et al.  The Fatty Acid Lipid Metabolism Nexus in COVID-19 , 2021, Viruses.

[11]  N. Hoertel,et al.  Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19 , 2020, Clinical Drug Investigation.

[12]  Esben B. Svenningsen,et al.  SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate , 2020, Nature Communications.

[13]  Shao-bo Shi,et al.  Chronic sigma-1 receptor activation ameliorates ventricular remodeling and decreases susceptibility to ventricular arrhythmias after myocardial infarction in rats. , 2020, European journal of pharmacology.

[14]  J. Lennerstrand,et al.  Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro , 2020, Redox Biology.

[15]  K. Jeevaratnam,et al.  Is the sigma-1 receptor a potential pharmacological target for cardiac pathologies? A systematic review , 2019, International journal of cardiology. Heart & vasculature.

[16]  Ying Wang,et al.  Sigma-1 receptor activation ameliorates LPS-induced NO production and ROS formation through the Nrf2/HO-1 signaling pathway in cultured astrocytes , 2019, Neuroscience Letters.

[17]  R. Shaw,et al.  AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. , 2017, Molecular cell.

[18]  K. Fukunaga,et al.  Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure. , 2013, Journal of pharmacological sciences.